U.S. Markets open in 7 hrs 19 mins
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.5418%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.4601%)
     
  • BTC-USD

    62,419.50
    +1,735.03 (+2.86%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Perfusio Corp’s FIRST Study Passes 100 Patient Milestone for its Perfusio-ARMUS Cloud Repository

·4 min read

GREENVILLE, N.C., September 21, 2021--(BUSINESS WIRE)--Perfusio Corp, a medical device company pioneering real-time visualization of perfusion and blood flow through its Certes™ surgical imaging technology, has captured over 100 patient images in its First-In-person Study (FIRST) into the Perfusio-ARMUS Cloud Repository. The FIRST study’s 100-patient milestone solidifies the foundation for the continued growth of the Certes™ platform’s AI machine learning capability for future predictive analytics intended to assist surgeons with immediate real time blood flow and perfusion visualization.

The FIRST Study, designed as a multi-site study, currently has twenty-five physicians across nine surgical sub-specialties that are Investigators in the Study. (Certes™ use is not restricted to a specific subspecialty or procedure as part of its FDA 510(k) Class II clearance.)

"The potential for the Certes™ platform to visualize, in real time, possible surgical complications, mitigate them and improve patient outcomes is astounding," commented Gyula Sziraczky, CEO of ARMUS. "This milestone for surgical image capture sets the foundation for continued learning and predictive analytics - a true game-changer for any time a surgeon needs to see immediate perfusion and blood flow in the surgical suite."

"This is a major accomplishment for our company," commented Monte B. Tucker, CEO of Perfusio. "The Perfusio-ARMUS Repository can now expand at an exponential rate to truly support predictive analytics – in real time – of perfusion and blood flow in the surgical setting."

The Perfusio-ARMUS Cloud Repository serves as the ‘back end’ of Perfusio’s knowledge platform, based on the company’s Multi-spectral Physiologic Visualization (MSPV) medical imaging technology solutions. MSPV captures, analyzes and displays the true dynamic physiology of perfusion and blood flow in intact and diseased tissues, in immediate real time. Unlike other real-time surgical imaging devices, MSPV incorporated into the Certes device is non-contact, non-invasive, has no need for dyes or contrast agents, and doesn’t use ionizing radiation. On the device, the immediate display of dynamic perfusion analytics is AI-based – new knowledge for surgeons that is not available in current standard-of-care practice. After completion of the procedure, these data are securely uploaded from the device into the Perfusio-ARMUS Repository. Surgeons can access their own patients’ data via the secure Surgeon Web Portal for viewing, comparing, and learning additional new knowledge about blood flow distribution in tissues.

About Perfusio Corp and Certes™

Perfusio Corp is a Greenville, North Carolina-based medical device company committed to the development and commercialization of innovative and transformational platform technologies for non-invasive surgical imaging. FDA-cleared in 2019 as iCertainty™, Certes™ by Perfusio allows surgeons to see the dynamic physiology of blood flow and perfusion in surgical tissues, using a proprietary combination of multi-spectral imaging and AI-enhanced laser speckle contrast analytics with immediate real-time display of quantified tissue perfusion. This visualization cannot be seen in current standard-of-care practice with the human eye and visible light. With Certes™, the surgeon has immediate new knowledge to determine where normal and sub-normal tissue perfusion is present. Since dyes and ionizing radiation are not used, imaging can be repeated as often as needed before, during, and after the procedure. With this new knowledge, surgeons identify and fix problems, avoid potential complications, and improve patient outcomes. Documentation survives the procedure using a cloud-based image repository for benchmarking, post-surgical review, future machine learning, and predictive analytics. Perfusio holds an exclusive license to 14 patents surrounding its technologies, with more than 20 additional patents under review.

About ARMUS

ARMUS Corporation, a Silicon Valley based clinical registry development and advanced data analytics company, has provided cybersecure data capture and reporting services to hundreds of institutions in the U.S. and around the world for more than twenty years. Our customers include premiere medical societies, large healthcare organizations, academic centers, and medical device companies. ARMUS’ proprietary HYBRID technology platform allows development of clinical registries at lightning speed, data transfer from any other complex registry or device, and translation of data into actionable reporting. Our most advanced AI powered analytic and reporting solutions enable healthcare providers to make educated decisions that result in optimal clinical and financial outcomes. HYBRID is accessible on the most advanced Google Cloud Platform around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005131/en/

Contacts

Monte B. Tucker, monte.tucker@perfusio.com, 252-656-0404